Riverview Bancorp reported a net income of $2.0 million, or $0.10 per diluted share, for the second quarter of fiscal 2027, marking its highest earnings in 12 quarters. The bank saw increased net interest income of $11.8 million and a net interest margin of 3.40%, driven by higher loan yields and balance sheet optimization. Total loans grew by $14.5 million to $1.11 billion, supported by a strong loan pipeline of $139.6 million. Despite a slight rise in non-interest expenses, the bank maintained disciplined cost management and declared a $0.02 per share dividend, positioning itself for continued growth and profitability.
Riverview Bancorp's second quarter 2027 results provide context for financial sector activity. For readers following Financials, here is Pluang's market snapshot as of Oct 28, 2026 02:21 WIB: out of 142 priced stocks, 89 rose and 53 fell. Notable movers include GEMI at USD 3.13 with a 9.23% increase and 100% sell order activity, PURR at USD 9.88 with an 8.88% rise and 100% buy order activity, and GLXY at USD 16.99 with an 8.35% gain.
The global drone defense system market is projected to grow from $4.72 billion in 2025 to $18.19 billion by 2030, driven by increasing unauthorized drone incidents and demand for advanced detection and countermeasure technologies. Growth is fueled by...
Eli Lilly has outpaced Novo Nordisk in the GLP-1, obesity, and Type 2 Diabetes market, achieving a $1.21 trillion valuation. While Novo Nordisk's share price has fallen back after earlier gains and revenue growth remains flat, its management's strate...
argenx SE announced it will stop its Phase 3 UNITY study of efgartigimod subcutaneous for moderate-to-severe Sjögren's disease after an independent committee found the trial unlikely to meet its primary goal. This decision caused the company's stock ...
Pomerantz LLP is investigating DaVita Inc. for potential securities fraud following a sharp stock price drop triggered by a new U.S. federal strategy targeting the dialysis market. The Department of Health and Human Services announced a plan to incre...
Pomerantz LLP is investigating ClearPoint Neuro and its executives for possible securities fraud following a significant stock price drop. The decline occurred after ClearPoint's partner, uniQure, announced that their Huntington's disease treatment f...
